Truist Financial Lowers Intuitive Surgical (NASDAQ:ISRG) Price Target to $605.00

Intuitive Surgical (NASDAQ:ISRG) had its price target trimmed by Truist Financial from $666.00 to $605.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Several other analysts also recently issued reports on ISRG. Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $522.00 to $650.00 in a research note on Monday, December 2nd. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Evercore ISI boosted their target price on shares of Intuitive Surgical from $490.00 to $530.00 in a research note on Monday, January 27th. Barclays boosted their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, Piper Sandler reissued an “overweight” rating and set a $670.00 target price (up from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $610.19.

Intuitive Surgical Stock Up 0.9 %

Shares of NASDAQ:ISRG opened at $488.80 on Monday. The company’s fifty day moving average is $566.38 and its two-hundred day moving average is $531.96. Intuitive Surgical has a 12-month low of $364.17 and a 12-month high of $616.00. The company has a market cap of $174.10 billion, a P/E ratio of 76.26, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43.

Insider Buying and Selling

In other Intuitive Surgical news, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the completion of the sale, the chief financial officer now directly owns 2,630 shares in the company, valued at $1,502,019.30. This represents a 3.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 11,545 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the sale, the executive vice president now owns 5,224 shares of the company’s stock, valued at $2,607,925.28. This trade represents a 68.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,754 shares of company stock worth $17,691,621. Corporate insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Hedge funds have recently bought and sold shares of the company. Atala Financial Inc bought a new stake in Intuitive Surgical during the fourth quarter valued at about $25,000. Hurley Capital LLC bought a new stake in Intuitive Surgical during the fourth quarter valued at about $28,000. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter valued at about $26,000. Parvin Asset Management LLC bought a new stake in shares of Intuitive Surgical in the fourth quarter valued at about $26,000. Finally, BankPlus Trust Department bought a new stake in shares of Intuitive Surgical in the fourth quarter valued at about $28,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.